<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459457</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>The Impact of Infliximab on Hyperinflammation State in Hospitalized COVID-19 Patients: A Retrospective Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1670</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina60101670</ELocationID><Abstract><AbstractText><i>Background and Objectives:</i> Elevated levels of pro-inflammatory cytokines have been linked to increased mortality in COVID-19 patients. Infliximab, a tumor necrosis factor inhibitor, has been reported to improve outcomes in COVID-19 patients by targeting the hyperinflammatory response. Our objective was to evaluate the effectiveness of incorporating Infliximab into standard care guidelines for the management of COVID-19. <i>Materials and Methods</i>: A retrospective analysis was conducted on 111 participants who were moderate to severe COVID-19 patients admitted to the hospital. Among them, 74 individuals received solely standard treatment, while 37 received standard therapy plus Infliximab. The primary outcomes of the study centered around the changes in laboratory test parameters. The secondary clinical findings included clinical recovery defined as improvement in patient oxygenation, time till recovery, and assessing necessity for ICU admission, and mortality rates. <i>Results:</i> There was no statistical difference observed in the inflammatory markers including, LDH, Ferritin, CRP, neutrophil to lymphocyte ratio (NLR), and P/F ratio between both groups and in the clinical outcomes including clinical recovery (<i>p</i> = 1.0), time to improvement (<i>p</i> = 0.436), and mortality rate (<i>p</i> = 0.601). However, there was a significant increase in secondary infection (45.9%, 20.3%; <i>p</i> = 0.005), and in liver enzymes, ALT (79.5, 50.0 IU/L; <i>p</i> = 0.02) and AST (57.5, 38.0 IU/L; <i>p</i> = 0.019) in the Infliximab group and the standard care group, respectively. <i>Conclusions:</i> Infliximab therapy did not demonstrate significant benefits compared to standard of care in moderate to severe hospitalized COVID-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saied</LastName><ForeName>Yasmine M</ForeName><Initials>YM</Initials><Identifier Source="ORCID">0000-0002-3106-0415</Identifier><AffiliationInfo><Affiliation>Microbiology and Immunology Postgraduate Program, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou Warda</LastName><ForeName>Ahmed Essam</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0003-4434-6217</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacy Department, Faculty of Pharmacy, October 6 University, Giza 12585, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allam</LastName><ForeName>Rasha Mahmoud</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology and Biostatistics, National Cancer Institute, Cairo University, Cairo 11796, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syed</LastName><ForeName>Wajid</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-4077-4524</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basil A Al-Rawi</LastName><ForeName>Mahmood</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Optometry, College of Applied Medical Sciences, King Saud University, Riyadh 11451, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Ayesha</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7282-471X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy Practice and Policy, University Park Campus, University of Nottingham, Nottingham NG7 2QL, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Office of Lifelong Learning and the Physician Learning Program, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G1C9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elgendy</LastName><ForeName>Marwa O</ForeName><Initials>MO</Initials><Identifier Source="ORCID">0000-0002-5466-0552</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Beni-Suef University Hospitals, Beni-Suef University, Beni-Suef 62521, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Nahda University (NUB), Beni-Suef 62764, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M El-Sabaa</LastName><ForeName>Ramy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Pharmacy Department, Faculty of Pharmacy, Menoufia University, Menoufia 32511, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0078-0310</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacy Department, Faculty of Pharmacy, University of Sadat City, Menoufia 32897, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>(RSP2024R378)</GrantID><Agency>King Saud University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="Y">Infliximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">infliximab</Keyword><Keyword MajorTopicYN="N">pro-inflammatory cytokines</Keyword><Keyword MajorTopicYN="N">standard of care</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459457</ArticleId><ArticleId IdType="pmc">PMC11509666</ArticleId><ArticleId IdType="doi">10.3390/medicina60101670</ArticleId><ArticleId IdType="pii">medicina60101670</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard with Vaccination Data.  [(accessed on 6 September2023)].  Available online:  https://data.who.int/dashboards/covid19/cases?n=c#:~:text=Globally%2C.</Citation></Reference><Reference><Citation>Jin Y., Yang H., Ji W., Wu W., Chen S., Zhang W., Duan G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12:372. doi: 10.3390/v12040372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12040372</ArticleId><ArticleId IdType="pmc">PMC7232198</ArticleId><ArticleId IdType="pubmed">32230900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324:782–793. doi: 10.1001/jama.2020.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimraj A., Morgan R.L., Shumaker A.H., Baden L., Cheng V.C.C., Edwards K.M., Gallagher J.C., Gandhi R.T., Muller W.J., Nakamura M.M., et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19. Clin. Infect. Dis. 2024;78:e250–e349. doi: 10.1093/cid/ciac724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac724</ArticleId><ArticleId IdType="pmc">PMC9494372</ArticleId><ArticleId IdType="pubmed">36063397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokkotis G., Kitsou K., Xynogalas I., Spoulou V., Magiorkinis G., Trontzas I., Trontzas P., Poulakou G., Syrigos K., Bamias G. Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments. Aliment. Pharmacol. Ther. 2021;55:154–167. doi: 10.1111/apt.16717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.16717</ArticleId><ArticleId IdType="pubmed">34881430</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarhan R.M., Altyar A.E., Warda A.E.A., Saied Y.M., Ibrahim H.S.G., Schaalan M.F., Fathy S., Sarhan N., Boshra M.S. Pentoxifylline Effects on Hospitalized COVID-19 Patients with Cytokine Storm Syndrome: A Randomized Clinical Trial. Pharmaceuticals. 2023;16:631. doi: 10.3390/ph16040631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16040631</ArticleId><ArticleId IdType="pmc">PMC10142327</ArticleId><ArticleId IdType="pubmed">37111389</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson P.C., Liew D.F., Liew J.W., Monaco C., Richards D., Shivakumar S., Tanner H.L., Feldmann M. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. Med. 2020;1:90–102. doi: 10.1016/j.medj.2020.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2020.11.005</ArticleId><ArticleId IdType="pmc">PMC7713589</ArticleId><ArticleId IdType="pubmed">33294881</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Li S., Liu J., Liang B., Wang X., Wang H., Li W., Tong Q., Yi J., Zhao L., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102763</ArticleId><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Velez M.P., McCarthy M.W. Infliximab as a potential treatment for COVID-19. Expert Rev. Anti-Infect. Ther. 2023;21:1–5. doi: 10.1080/14787210.2023.2151438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2023.2151438</ArticleId><ArticleId IdType="pubmed">36413380</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarhan N.M., Warda A.E.A., Ibrahim H.S.G., Schaalan M.F., Fathy S.M. Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome. Sci. Rep. 2023;13:6456. doi: 10.1038/s41598-023-33484-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-33484-6</ArticleId><ArticleId IdType="pmc">PMC10116445</ArticleId><ArticleId IdType="pubmed">37081046</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinger M.T., Person H., Smith R., Jarchin L., Pittman N., Dubinsky M.C., Lai J. Pediatric Crohn’s Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab. J. Pediatr. Gastroenterol. Nutr. 2020;71:153–155. doi: 10.1097/MPG.0000000000002809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000002809</ArticleId><ArticleId IdType="pmc">PMC7268863</ArticleId><ArticleId IdType="pubmed">32452979</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang S., Dai J., Hou S., Su L., Zhang D., Guo H., Hu S., Wang H., Rao Z., Guo Y., et al. Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab. J. Biol. Chem. 2013;288:13799–13807. doi: 10.1074/jbc.M112.433961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.433961</ArticleId><ArticleId IdType="pmc">PMC3650416</ArticleId><ArticleId IdType="pubmed">23504311</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrokhpour M., Rezaie N., Moradi N., Rad F.G., Izadi S., Azimi M., Zamani F., Izadi S., Ranjbar M., Makiani M.J., et al. Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit. Arch. Iran. Med. 2021;24:139–143. doi: 10.34172/aim.2021.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/aim.2021.22</ArticleId><ArticleId IdType="pubmed">33636983</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurath M.F. COVID-19 and immunomodulation in IBD. Gut. 2020;69:1335–1342. doi: 10.1136/gutjnl-2020-321269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321269</ArticleId><ArticleId IdType="pmc">PMC7211083</ArticleId><ArticleId IdType="pubmed">32303609</ArticleId></ArticleIdList></Reference><Reference><Citation>A Fisher B., Veenith T., Slade D., Gaskell C., Rowland M., Whitehouse T., Scriven J., Parekh D., Balasubramaniam M.S., Cooke G., et al. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): A randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respir. Med. 2021;10:255–266. doi: 10.1016/S2213-2600(21)00460-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00460-4</ArticleId><ArticleId IdType="pmc">PMC8676420</ArticleId><ArticleId IdType="pubmed">34922649</ArticleId></ArticleIdList></Reference><Reference><Citation>O’halloran J.A., Ko E.R., Anstrom K.J., Kedar E., McCarthy M.W., Panettieri R.A., Maillo M., Nunez P.S., Lachiewicz A.M., Gonzalez C., et al. Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA. 2023;330:328–339. doi: 10.1001/jama.2023.11043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.11043</ArticleId><ArticleId IdType="pmc">PMC10334296</ArticleId><ArticleId IdType="pubmed">37428480</ArticleId></ArticleIdList></Reference><Reference><Citation>Amani B., Zareei S., Amani B., Zareei M., Zareei N., Shabestan R., Akbarzadeh A. Artesunate, imatinib, and infliximab in COVID-19: A rapid review and meta-analysis of current evidence. Immun. Inflamm. Dis. 2022;10:e628. doi: 10.1002/iid3.628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.628</ArticleId><ArticleId IdType="pmc">PMC9092000</ArticleId><ArticleId IdType="pubmed">35634954</ArticleId></ArticleIdList></Reference><Reference><Citation>Izadi Z., Brenner E.J., Mahil S.K., Dand N., Yiu Z.Z.N., Yates M., Ungaro R.C., Zhang X., Agrawal M., Colombel J.-F., et al. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Netw. Open. 2021;4:e2129639. doi: 10.1001/jamanetworkopen.2021.29639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.29639</ArticleId><ArticleId IdType="pmc">PMC8524310</ArticleId><ArticleId IdType="pubmed">34661663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousaf A., Gayam S., Feldman S., Zinn Z., Kolodney M. Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study. J. Am. Acad. Dermatol. 2021;84:70–75. doi: 10.1016/j.jaad.2020.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.09.009</ArticleId><ArticleId IdType="pmc">PMC7484805</ArticleId><ArticleId IdType="pubmed">32926977</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y., Hu K., Li Y., Lu C., Ling K., Cai C., Wang W., Ye D. Targeting TNF-α for COVID-19: Recent Advanced and Controversies. Front. Public Health. 2022;10:833967. doi: 10.3389/fpubh.2022.833967.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.833967</ArticleId><ArticleId IdType="pmc">PMC8873570</ArticleId><ArticleId IdType="pubmed">35223745</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Egede L.E., Walker R.J. Structural Racism, Social Risk Factors, and Covid-19—A Dangerous Convergence for Black Americans. N. Engl. J. Med. 2020;383:e77. doi: 10.1056/NEJMp2023616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2023616</ArticleId><ArticleId IdType="pmc">PMC7747672</ArticleId><ArticleId IdType="pubmed">32706952</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N., Damoraki G., Gkavogianni T., Adami M.-E., Katsaounou P., et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27:992–1000.e3. doi: 10.1016/j.chom.2020.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz M., Fatima R., Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J. Med. Virol. 2020;92:2283–2285. doi: 10.1002/jmv.25948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25948</ArticleId><ArticleId IdType="pmc">PMC7267383</ArticleId><ArticleId IdType="pubmed">32343429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Pang J., Ji P., Zhong Z., Li H., Li B., Zhang J. Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis. J. Med. Virol. 2020;93:35–37. doi: 10.1002/jmv.26085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26085</ArticleId><ArticleId IdType="pmc">PMC7283812</ArticleId><ArticleId IdType="pubmed">32470146</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold T., Jurinovic V., Arnreich C., Lipworth B.J., Hellmuth J.C., von Bergwelt-Baildon M., Klein M., Weinberger T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 2020;146:128–136.e4. doi: 10.1016/j.jaci.2020.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7233239</ArticleId><ArticleId IdType="pubmed">32425269</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldmann M., Maini R.N., Woody J.N., Holgate S.T., Winter G., Rowland M., Richards D., Hussell T. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395:1407–1409. doi: 10.1016/S0140-6736(20)30858-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30858-8</ArticleId><ArticleId IdType="pmc">PMC7158940</ArticleId><ArticleId IdType="pubmed">32278362</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson P.C., Richards D., Tanner H.L., Feldmann M. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol. 2020;2:e653–e655. doi: 10.1016/S2665-9913(20)30309-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30309-X</ArticleId><ArticleId IdType="pmc">PMC7832144</ArticleId><ArticleId IdType="pubmed">33521660</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D.M., Kim-Schulze S., Huang H.-H., Beckmann N.D., Nirenberg S., Wang B., Lavin Y., Swartz T.H., Madduri D., Stock A., et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020;26:1636–1643. doi: 10.1038/s41591-020-1051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner E.J., Ungaro R.C., Gearry R.B., Kaplan G.G., Kissous-Hunt M., Lewis J.D., Ng S.C., Rahier J.-F., Reinisch W., Ruemmele F.M., et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020;159:481–491.e3. doi: 10.1053/j.gastro.2020.05.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.032</ArticleId><ArticleId IdType="pmc">PMC7233252</ArticleId><ArticleId IdType="pubmed">32425234</ArticleId></ArticleIdList></Reference><Reference><Citation>The RECOVERY Collaborative Group Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Taleng C.M.M.P., Lauper K., Gilbert B., Cunningham T., Guemara R., Brulhart L., Dan D., Courvoisier D., Finckh A. Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab. RMD Open. 2021;7:e001711. doi: 10.1136/rmdopen-2021-001711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001711</ArticleId><ArticleId IdType="pmc">PMC8646967</ArticleId><ArticleId IdType="pubmed">34862310</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallmach A., Kortgen A., Gonnert F., Coldewey S.M., Reuken P., Bauer M. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure—A cautionary case series. Crit. Care. 2020;24:1–3. doi: 10.1186/s13054-020-03158-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03158-0</ArticleId><ArticleId IdType="pmc">PMC7366555</ArticleId><ArticleId IdType="pubmed">32680535</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachem H., Godara A., Schroeder C., Fein D., Mann H., Lawlor C., Marshall J., Klein A., Poutsiaka D., Breeze J.L., et al. Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. J. Clin. Transl. Sci. 2021;5:e146. doi: 10.1017/cts.2021.805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cts.2021.805</ArticleId><ArticleId IdType="pmc">PMC8376916</ArticleId><ArticleId IdType="pubmed">34457357</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Ke J., Jiang X., Wang L. The association between ulcerative colitis and COVID-19 severity: A systematic review and meta-analysis systematic review. Int. J. Color. Dis. 2023;39:5. doi: 10.1007/s00384-023-04568-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-023-04568-6</ArticleId><ArticleId IdType="pubmed">38108846</ArticleId></ArticleIdList></Reference><Reference><Citation>Shayan S.K., Nasrollahi E., Bahramvand Y., Zarei M., Atarodi A., Farsi Y., Tavakolizadeh M., Shirvaliloo M., Abbasifard M., Jamialahmadi T., et al. Percutaneous Coronary Intervention Associated with a Higher Risk of Hypoxemia and COVID-19 Severity. Curr. Med. Chem. 2024;31:1265–1277. doi: 10.2174/0929867330666230222104345.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867330666230222104345</ArticleId><ArticleId IdType="pubmed">36815635</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournia V.-K., E Fragoulis G., Mitrou P., Mathioudakis K., Konstantonis G., Tektonidou M.G., Tsolakidis A., Paraskevis D., Sfikakis P.P. Outcomes of COVID-19 Omicron variant in patients with rheumatoid arthritis: A nationwide Greek cohort study. Rheumatology. 2023;63:1130–1138. doi: 10.1093/rheumatology/kead354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kead354</ArticleId><ArticleId IdType="pmc">PMC10986801</ArticleId><ArticleId IdType="pubmed">37467059</ArticleId></ArticleIdList></Reference><Reference><Citation>Notley C.A., Inglis J.J., Alzabin S., McCann F.E., McNamee K.E., Williams R.O. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J. Exp. Med. 2008;205:2491–2497. doi: 10.1084/jem.20072707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20072707</ArticleId><ArticleId IdType="pmc">PMC2571924</ArticleId><ArticleId IdType="pubmed">18936235</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>